First Quarter of the Fiscal Year Ending March 31, 2027
Sales composition ratio
Pharmaceutical Wholesale Business
In the pharmaceutical wholesale business, although there were slight negative impacts from the drug price revision, revenue increased due to efforts to focus on the sale of products eligible for the Patent-period price Maintenance Program for Innovative Drugs (PMP), mainly anticancer drugs. On the profit side, although there were increases in selling, general and administrative expenses due to the recording of expenses related to various DX initiatives and rising prices such as fuel costs, profit increased due to the revenue growth effect. As a result of the above, net sales were 144,979 million yen (104.3% of the same period of the previous year), and segment profit (operating profit) was 1,103 million yen (101.9% of the same period of the previous year).
Pharmacy Business
In the pharmacy business, although the number of prescriptions decreased, revenue increased slightly due to efforts to increase income from dispensing technical fees and pharmaceutical management fees. On the profit side, despite efforts to calculate dispensing fees related to family pharmacy functions and to manage costs, profit decreased due to factors such as the impact of the dispensing fee and drug price revisions. As a result of the above, net sales were 4,894 million yen (101.1% of the same period of the previous year), and segment loss (operating loss) was 60 million yen (segment profit of 42 million yen for the same period of the previous year).
Veterinary Drug Wholesale Business
In the Veterinary Drug Wholesale Business, revenue remained almost at the same level as the previous year, partly due to intensifying sales competition. On the profit side, despite efforts to manage costs, profit decreased slightly as the increase in personnel and fuel costs could not be absorbed. As a result of the above, net sales were 3,077 million yen (99.7% of the same period of the previous year), and segment profit (operating profit) was 73 million yen (94.5% of the same period of the previous year).
Pharmaceutical Business (business of supporting introduction of unapproved drugs)
The Pharmaceutical Business (business of supporting introduction of unapproved drugs) is a new business launched in September 2025, and no sales were posted in the first quarter of the current consolidated fiscal year, while expenses necessary for business activities including research and development expenses came to 420 million yen, and segment loss amounted to the same amount of 420 million yen.
Nursing Care-related Rental and Other Business
In the Nursing Care-related Rental and Other Business, revenue increased due to factors including the consolidation of Yachiyo Care Holdings Co., Ltd. in December 2025. On the profit side, although there were increases in selling, general and administrative expenses due to rising prices such as personnel and fuel costs, the segment loss narrowed due to the revenue growth effect. As a result, net sales were 1,648 million yen (127.7% of the same period of the previous year), and segment loss (operating loss) was 61 million yen (segment loss of 85 million yen for the same period of the previous year).